Lawrence Eichenfield, MD, provides the newest updates in pediatric patient care, with a special update on COVID-19 skin symptoms in children.
Cantharidin 0.7% could be an emerging standard for molluscum treatment.
Ted Rosen, MD, and Sheila Fallon Friedlander, MD, discuss infectious disease updates at the virtual Maui Derm NP+PA Fall 2021 conference.
At Maui Derm NP+PA Fall 2021, Vikash S. Oza, MD, and Matthew J. Zirwas, MD, discuss the current Rx and Dx of atopic dermatitis in children.
According to a study in Annals of Dermatology and Venerology, pediatric patients with psoriasis in France frequently missed dermatologic consultations.
Some systemic medications may have increased risk for patients during the COVID-19 era, according to a recent Pediatric Dermatology Research Alliance (PeDRA) statement.
COVID-19’s lingering impact brings new considerations for treatment regimens for pediatric patients with psoriasis.
Many conditions are different in the pediatric population than in the adult population. How does hidradenitis suppurativa differ between the 2 groups?
A phase 3 trial studied the effectiveness of oral abrocitinib along with topical therapy for moderate-to-severe atopic dermatitis in teens.
In this episode, Alberto Pappo, MD, director, St. Jude Solid Tumor Division, discusses a registry he helped create aimed at helping physicians better understand pediatric melanoma called Molecular Analysis of Childhood MELanocytic Tumors (MACMEL).